In the past three months, 5 analysts have weighed in on KORU Scientific Programs ( NASDAQ:KRMD ), offering a range of opinions, ranging from bullish to bearish.
The table below provides a summary of their current ratings, showing changing sentiment over the past 30 days and ranking them against previous months.
| Bullish | Rather bullish | Indifferent | Rather a bear | Bears | |
|---|---|---|---|---|---|
| Full marks | 4 | 1 | 0 | 0 | 0 |
| The ultimate 30D | 1 | 0 | 0 | 0 | 0 |
| 1 m ago | 1 | 0 | 0 | 0 | 0 |
| 2 m ago | 0 | 0 | 0 | 0 | 0 |
| 3 m ago | 2 | 1 | 0 | 0 | 0 |
Analysts focus on KORU’s recently assessed science programs and equipped 12-month tracking targets. The moderate target is $4.7, along with a $6.00 high estimate and a $3.50 low estimate. The most recent moderate price exceeded the outdated moderate target of $3.80 and rose 23.68%.
Decoding Analyst Ratings: A Detailed Impression
An in-depth diagnosis of contemporary analytical actions reveals how financial experts view KORU’s scientific programs. The following summary describes key analysts, their current estimates and adjustments to estimates and target rates.
| an analyst | Analytical agency | Chase Taken | result | Recent Named Target | Preliminary goal |
|---|---|---|---|---|---|
| Jog Knickerbocker | Craig-Hallum | He’s lifting | Get it | $6.00 | $5.00 |
| Frank Takkinen | Lake Avenue | He’s lifting | Get it | $5.00 | $4.00 |
| Jog Knickerbocker | Craig-Hallum | He’s lifting | Get it | $5.00 | $4.00 |
| Caitlin Cronin | Canaccord Genuity | He’s lifting | Get it | $4.00 | $3.00 |
| Jason Bednar | Piper Sandler | He’s lifting | Chubby | $3.50 | $3.00 |
Key Insights: Execution: When protecting against dynamic market conditions and business performance, analysts update their propositions. Whether they ‘maintain’, ‘raise’ or ‘lower’ their stance, this means their response to contemporary trends associated with KORU’s scientific programs. This insight provides a snapshot of analysts’ views on the company’s state-of-the-art. Rating: Digging into ratings, analysts place qualitative values ranging from ‘Outperform’ to ‘Underperform’. These ratings speak to expectations regarding the relative performance of KORU’s science programs compared to the broader market. Set Goals: Forecasting analysts provide estimates for the future of KORU Scientific Programs. Examining state-of-the-art and prior targets provides insight into changing analyst expectations.
Compiling these analytical estimates along with key financial ratios can provide valuable insight into the market position of KORU Scientific Programs. Stay informed and make a smart informed choice with our rating chart.
Stop waking up at this level on KORU Scientific Programs analyst ratings.
While you are willing to follow small news and performance, there is no doubt that you may well originate following here.
About KORU’s scientific programs
KORU Scientific Programs Inc is a developer and manufacturer of medical devices and provides Focuses on mechanical infusion products, FREEDOM infusion programs. Its flagship products include the Freedom Infusion Machine: FREEDOM60 and FreedomEdge Syringe Drivers, Precision Wander with skedaddle Price Tubing, HIgH-Flo Subcutaneous Safety Needle Devices and Precision Wander with skedaddle Price Tubing. It is a manufacturer of subcutaneous infusion devices that delivers persistent immunoglobulin therapies to patients with conditions such as dominant immunodeficiency (PIDD) and persistent inflammatory demyelinating polyneuropathy (CIDP).
Financial effectiveness of KORU’s scientific programs
Market Capitalization Analysis: The company’s market capitalization exceeds industry averages, indicating a dominant size compared to peers and indicating a solid market position.
Earning Status: KORU science programs shown positive finally end in 3 months. By September 30, 2024, the company has achieved reliable revenue growth of approximately 16.8%. This means a marked increase in the company’s top profit. When placed next to others in the healthcare sector, the company faces challenges achieving development cost reductions as moderate among peers.
Opt for higher margin: KORU Scientific Programs’ purchase margin exceeds industry benchmarks at -19.33%. This means effective tracking management and being a reliable financial savvy being.
Return on Equity (ROE): KORU Scientific Programs’ ROE exceeds industry benchmarks at -8.68%. This means solid financial management and efficient use of equity capital.
Return on Assets (ROA): KORU Scientific Programs’ financial strength is reflected in its characteristic ROA, which exceeds industry averages. With a noteworthy ROA of -5.78%, the company demonstrates efficient use of resources and sound financial acumen.
Debt Management: KORU Scientific Programs’ debt-to-equity ratio is below the industry average at 0.24, reflecting a lower reliance on debt financing and an extremely conservative financial methodology.
Fundamentals of Analyst Ratings
Within banking and finance methods, analysts specialize in reporting for specific stocks or specific sectors. Their work involves attending company conference calls and meetings, researching the company’s financial statements, and talking to insiders to provide “analyst ratings” for the stock. Analysts constantly rate and charge each stock immediately on a quarterly basis.
Some analysts also offer forecasts for valuable metrics similar to earnings, revenue and development estimates to provide further guidance on what to produce with decided tickers. You will need to keep in mind that while stock and sector analysts are experts, they are also human and can easily project their beliefs to traders.
Breaking: Wall Avenue The Next Mammoth Mover
Benzinga’s first analyst correctly identified a stock poised for explosive growth. This under-the-radar company could very well likely rise 200%+ as major market moves unfold. Click here to print the fine print.
This article was generated by Benzinga’s computerized citation engine and reviewed by an editor.
Latest ratings for KRMD
| The date | Agency | Chase | From | For |
|---|---|---|---|---|
| January 2021 | Canaccord Genuity | Reductions | Get it | Keep it |
| January 2021 | Piper Sandler | Reductions | Chubby | Only |
| November 2020 | Canaccord Genuity | It maintains | Get it |
More analyst ratings for KRMD
Read the latest analyst ratings
© 2025 Benzinga.com. Benzinga does not make investment recommendations. All rights reserved.
The views and opinions expressed herein are those of the author and are fictional and do not necessarily reflect those of Nasdaq, Inc.
Leave a Reply